Samik Pharm

At a glance

Samik Pharm filed 35 disclosures in the last 12 months, including 10 insider and 4 5% holder. The most recent key filing was on Oct 23: A major holder's stake fell from 60.27% to 59.44% (stock option).

Revenue for 2025 was ₩60B, up 7.5% on 2024. Operating margin was 5.5% against 6.6% a year earlier. Debt was 24% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩31.2B and operating profit of ₩701.6M.

The 2025 annual report lists 146 employees with an average tenure of 7.2 years and average pay of ₩54.9M, #1229 of 1,829 listed companies by average pay. Its 7 directors and auditors were paid ₩144M each on average. It paid ₩40 per common share in cash dividends, against ₩40 a year earlier (+0%). 이충환 and related parties held 63.49% at year end.

Of 1 recent 5%+ holder report, 0 raised and 1 cut a stake; the largest stake reported was 59.44% on Oct 23.

From the 2025 annual report

Staff: 146 (72 men, 74 women), of whom 4 on fixed-term contracts. Total pay for the year: ₩8.1B. Directors and auditors: 7, paid ₩1B in total.

Dividends (common shares)

Largest shareholder

이충환 holds 21.75%; with 15 related parties the group holds 63.49% of common shares at year end (from 81.32% at the start of the year).

Auditor: 정진세림회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary

5%+ holder reports